Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 19, Issue 1, 2017, Pages 33-39

  Linnebjerg, Helle ^a   Lam, Eric Chen Quin ^b   Zhang, Xin ^a   Seger, Mary E ^a   Coutant, David ^a   Chua, Laiyi ^b   Kapitza, Christoph ^c   Heise, Tim ^c  

^a ELI LILLY AND COMPANY   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Profil   (Germany)

Author keywords

basal insulin; biosimilar insulin; clinical trial; pharmacodynamics; phase I II study; type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN GLARGINE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; LY2963016 INSULIN GLARGINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFUSION RATE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT PLANNING; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; FEMALE; GLUCOSE CLAMP TECHNIQUE; METABOLISM; MIDDLE AGED; TIME FACTOR;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; MALE; MIDDLE AGED; TIME FACTORS;

EID: 85006873283     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12759     Document Type: Article

References (20)

1. ® (insulin glargine [rDNA origin] injection) solution for subcutaneous injection. Prescribing Information. https://products.sanofi.us/lantus/lantus.html. Accessed October 23, 2015.
2. Eli Lilly and Company. European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe. 2014. http://investor.lilly.com/releasedetail.cfm?ReleaseID=870088. Accessed October 23, 2015.
3. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500184161.pdf. Accessed October 23, 2015.
4. US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed October 23, 2015.
5. US Food and Drug Administration. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference protein product. Guidance for industry. 2015. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf. Accessed October 23, 2015.
6. Linnebjerg H, Lam ECQ, Seger ME, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care. 2015;38:2226–2233.
7. Benesch C, Heise T, Klein O, Heinemann L, Arnolds S. How to assess the quality of glucose clamps? Evaluation of clamps performed with ClampArt, a novel automated clamp device. J Diabetes Sci Technol. 2015;9:792–800.
8. Cox DR. Regression models and life-tables. J R Stat Soc Ser B. 1972;20:187–220.
9. ®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab. 2015;17:726–733.
10. Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17:734–741.
11. European Medicines Agency. Assessment report: Abasria. 2014. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002835/WC500175383.pdf. Accessed October 23, 2015.
12. Dowlat HA, Kuhlmann MK, Khatami H, Ampudia-Blasco FJ. Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications. Diabetes Obes Metab. 18:737–746.
13. Heise T, Hövelmann U, Nosek L, Hermanski L, Bøttcher SG, Haahr H. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol. 2015;11:1193–1201.
14. -1. Diabetes Care. 2015;38:637–643.
15. Porcellati F, Rossetti P, Ricci NB, et al. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care. 2007;30:1261–1263.
16. Heise T, Piebar TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9:648–659.
17. Koehler G, Treiber G, Wutte A, et al. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Diabetes Obes Metab. 2014;16:57–62.
18. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–2148.
19. Lucidi P, Porcellati F, Rossetti P, et al. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. Diabetes Care. 2011;34:1312–1314.
20. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614–1620.